118 related articles for article (PubMed ID: 18598736)
1. Interactions between antiparkinsonian drugs and ABCB1/P-glycoprotein at the blood-brain barrier in a rat brain endothelial cell model.
Vautier S; Milane A; Fernandez C; Buyse M; Chacun H; Farinotti R
Neurosci Lett; 2008 Sep; 442(1):19-23. PubMed ID: 18598736
[TBL] [Abstract][Full Text] [Related]
2. Minocycline and riluzole brain disposition: interactions with p-glycoprotein at the blood-brain barrier.
Milane A; Fernandez C; Vautier S; Bensimon G; Meininger V; Farinotti R
J Neurochem; 2007 Oct; 103(1):164-73. PubMed ID: 17635670
[TBL] [Abstract][Full Text] [Related]
3. ABCB1: the role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs.
Vautier S; Fernandez C
Expert Opin Drug Metab Toxicol; 2009 Nov; 5(11):1349-58. PubMed ID: 19663741
[TBL] [Abstract][Full Text] [Related]
4. Exposure to antiepileptic drugs does not alter the functionality of P-glycoprotein in brain capillary endothelial and kidney cell lines.
Ambroziak K; Kuteykin-Teplyakov K; Luna-Tórtos C; Al-Falah M; Fedrowitz M; Löscher W
Eur J Pharmacol; 2010 Feb; 628(1-3):57-66. PubMed ID: 19958760
[TBL] [Abstract][Full Text] [Related]
5. Increased P-glycoprotein function and level after long-term exposure of four antiepileptic drugs to rat brain microvascular endothelial cells in vitro.
Yang HW; Liu HY; Liu X; Zhang DM; Liu YC; Liu XD; Wang GJ; Xie L
Neurosci Lett; 2008 Apr; 434(3):299-303. PubMed ID: 18313849
[TBL] [Abstract][Full Text] [Related]
6. Insulin regulates P-glycoprotein in rat brain microvessel endothelial cells via an insulin receptor-mediated PKC/NF-kappaB pathway but not a PI3K/Akt pathway.
Liu H; Yang H; Wang D; Liu Y; Liu X; Li Y; Xie L; Wang G
Eur J Pharmacol; 2009 Jan; 602(2-3):277-82. PubMed ID: 19049803
[TBL] [Abstract][Full Text] [Related]
7. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier.
Hsiao P; Bui T; Ho RJ; Unadkat JD
Drug Metab Dispos; 2008 Mar; 36(3):481-4. PubMed ID: 18057117
[TBL] [Abstract][Full Text] [Related]
8. Effect of p-glycoprotein inhibitor combinations on drug efflux from rat brain microvessel endothelial cells.
Yang ZY; Liu GQ
Pharmazie; 2004 Dec; 59(12):952-6. PubMed ID: 15638085
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein-mediated efflux of phenobarbital at the blood-brain barrier evidence from transport experiments in vitro.
Yang ZH; Liu XD
Epilepsy Res; 2008 Jan; 78(1):40-9. PubMed ID: 18063342
[TBL] [Abstract][Full Text] [Related]
10. A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes.
Nakagawa S; Deli MA; Kawaguchi H; Shimizudani T; Shimono T; Kittel A; Tanaka K; Niwa M
Neurochem Int; 2009; 54(3-4):253-63. PubMed ID: 19111869
[TBL] [Abstract][Full Text] [Related]
11. Chemical modification of paclitaxel (Taxol) reduces P-glycoprotein interactions and increases permeation across the blood-brain barrier in vitro and in situ.
Rice A; Liu Y; Michaelis ML; Himes RH; Georg GI; Audus KL
J Med Chem; 2005 Feb; 48(3):832-8. PubMed ID: 15689167
[TBL] [Abstract][Full Text] [Related]
12. Modulation of Pgp function by boswellic acids.
Weber CC; Reising K; Müller WE; Schubert-Zsilavecz M; Abdel-Tawab M
Planta Med; 2006 May; 72(6):507-13. PubMed ID: 16773534
[TBL] [Abstract][Full Text] [Related]
13. Potential impact of ABCB1 (p-glycoprotein) polymorphisms on avermectin toxicity in humans.
Macdonald N; Gledhill A
Arch Toxicol; 2007 Aug; 81(8):553-63. PubMed ID: 17354009
[TBL] [Abstract][Full Text] [Related]
14. P-glycoprotein contributes to the blood-brain, but not blood-cerebrospinal fluid, barrier in a spontaneous canine p-glycoprotein knockout model.
Mealey KL; Greene S; Bagley R; Gay J; Tucker R; Gavin P; Schmidt K; Nelson F
Drug Metab Dispos; 2008 Jun; 36(6):1073-9. PubMed ID: 18332085
[TBL] [Abstract][Full Text] [Related]
15. Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier.
Choo EF; Kurnik D; Muszkat M; Ohkubo T; Shay SD; Higginbotham JN; Glaeser H; Kim RB; Wood AJ; Wilkinson GR
J Pharmacol Exp Ther; 2006 Jun; 317(3):1012-8. PubMed ID: 16537797
[TBL] [Abstract][Full Text] [Related]
16. Blood-brain barrier transport of pramipexole, a dopamine D2 agonist.
Okura T; Ito R; Ishiguro N; Tamai I; Deguchi Y
Life Sci; 2007 Apr; 80(17):1564-71. PubMed ID: 17307202
[TBL] [Abstract][Full Text] [Related]
17. The anti-Parkinson drug budipine is exported actively out of the brain by P-glycoprotein in mice.
Uhr M; Ebinger M; Rosenhagen MC; Grauer MT
Neurosci Lett; 2005 Jul 22-29; 383(1-2):73-6. PubMed ID: 15936515
[TBL] [Abstract][Full Text] [Related]
18. Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells.
Batrakova EV; Li S; Alakhov VY; Miller DW; Kabanov AV
J Pharmacol Exp Ther; 2003 Feb; 304(2):845-54. PubMed ID: 12538842
[TBL] [Abstract][Full Text] [Related]
19. Determinants of drug brain uptake in a rat model of seizure-associated malformations of cortical development.
Marchi N; Guiso G; Caccia S; Rizzi M; Gagliardi B; Noé F; Ravizza T; Bassanini S; Chimenti S; Battaglia G; Vezzani A
Neurobiol Dis; 2006 Dec; 24(3):429-42. PubMed ID: 17027274
[TBL] [Abstract][Full Text] [Related]
20. Does inhibition of P-glycoprotein lead to drug-drug interactions?
Balayssac D; Authier N; Cayre A; Coudore F
Toxicol Lett; 2005 Apr; 156(3):319-29. PubMed ID: 15763631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
